Moshe Talpaz
Impact in
- Hematology top 0.01%
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
- Genetics top 0.01%
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
Papers in
- Hematology 585
- Chronic Myeloid Leukemia Treatments 504
- Acute Myeloid Leukemia Research 128
- Genetics 430
- Chronic Lymphocytic Leukemia Research 298
- Myeloproliferative Neoplasms: Diagnosis and Treatment 137
- Co-authors
- Hagop Kantarjian (251 shared papers)Razelle Kurzrock (135 shared papers)Jörge E. Cortes (162 shared papers)Brian J. Druker (17 shared papers)Charles L. Sawyers (18 shared papers)Debra J. Resta (9 shared papers)Renaud Capdeville (6 shared papers)Zeev Estrov (82 shared papers)
- Journals
- Blood (245 papers)Cancer (68 papers)Journal of Clinical Oncology (36 papers)Leukemia (35 papers)British Journal of Haematology (19 papers)
- Partner nations
- United StatesItalyUnited Kingdom
In The Last Decade
Moshe Talpaz
777 papers receiving 57.8k citations
Moshe Talpaz's Hit Papers
Peers
Comparison fields: 5 of 167
- Hematology 35.5k
- Genetics 26.4k
- Rheumatology 14.1k
- Oncology 10.4k
- Pathology and Forensic Medicine 4.9k
Countries citing papers authored by Moshe Talpaz
This map shows the geographic impact of Moshe Talpaz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Moshe Talpaz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Moshe Talpaz more than expected).
Fields of papers citing papers by Moshe Talpaz
This network shows the impact of papers produced by Moshe Talpaz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Moshe Talpaz. The network helps show where Moshe Talpaz may publish in the future.
Co-authors
The 25 scholars most cited alongside Moshe Talpaz, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 797 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia Hit paper breakdown → | 2001 | 4270 |
| 2 | Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome Hit paper breakdown → | 2001 | 2286 |
| 3 | A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis Hit paper breakdown → | 2012 | 1715 |
| 4 | Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia Hit paper breakdown → | 2002 | 1706 |
| 5 | Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias Hit paper breakdown → | 2006 | 1437 |
| 6 | The Biology of Chronic Myeloid Leukemia Hit paper breakdown → | 1999 | 1050 |
| 7 | A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias Hit paper breakdown → | 2013 | 940 |
| 8 | Activating ESR1 mutations in hormone-resistant metastatic breast cancer Hit paper breakdown → | 2013 | 933 |
| 9 | Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study Hit paper breakdown → | 2002 | 874 |
| 10 | Phase I Safety and Pharmacokinetic Study of Recombinant Human Anti-Vascular Endothelial Growth Factor in Patients With Advanced Cancer Hit paper breakdown → | 2001 | 799 |
| 11 | The Molecular Genetics of Philadelphia Chromosome–Positive Leukemias Hit paper breakdown → | 1988 | 734 |
| 12 | Integrative clinical genomics of metastatic cancer Hit paper breakdown → | 2017 | 687 |
| 13 | Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing Hit paper breakdown → | 2013 | 633 |
| 14 | Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias Hit paper breakdown → | 2012 | 622 |
| 15 | Identification of Targetable FGFR Gene Fusions in Diverse Cancers Hit paper breakdown → | 2013 | 619 |
| 16 | 2002 | 565 | |
| 17 | Hematologic Remission and Cytogenetic Improvement Induced by Recombinant Human Interferon AlphaAin Chronic Myelogenous Leukemia Hit paper breakdown → | 1986 | 556 |
| 18 | 2011 | 534 | |
| 19 | Clinical toxicity of interferons in cancer patients: a review. Hit paper breakdown → | 1986 | 530 |
| 20 | Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial Hit paper breakdown → | 2018 | 454 |
About Moshe Talpaz
Moshe Talpaz is a scholar working on Hematology, Genetics, Rheumatology, Oncology and Pathology and Forensic Medicine, having authored 797 papers that have together received 60.5k indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (504 papers), Chronic Lymphocytic Leukemia Research (298 papers), Eosinophilic Disorders and Syndromes (160 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (137 papers), Acute Myeloid Leukemia Research (128 papers), Acute Lymphoblastic Leukemia research (83 papers), Lymphoma Diagnosis and Treatment (55 papers) and Cytokine Signaling Pathways and Interactions (43 papers). The work is most often cited by research in Hematology (35.5k citations), Genetics (26.4k citations), Rheumatology (14.1k citations), Oncology (10.4k citations) and Pathology and Forensic Medicine (4.9k citations). Moshe Talpaz has collaborated with scholars based in United States, Italy and United Kingdom. Frequent co-authors include Hagop Kantarjian, Razelle Kurzrock, Jörge E. Cortes, Brian J. Druker, Charles L. Sawyers, Debra J. Resta, Renaud Capdeville, Zeev Estrov, Stefan H Faderl and Jordan U. Gutterman. Their work appears in journals such as Blood, Cancer, Journal of Clinical Oncology, Leukemia and British Journal of Haematology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.